Welcome to the e-CCO Library!

OP023: Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, Schreiber S.2, Petryka R.3, Kuehbacher T.4, Hebuterne X.5, Roblin X.6, Klopocka M.7, Goldis A.8, Wisniewska-Jarosinska M.9, Baranovsky A.10, Sike R.11, Stoyanova K.12, Meuleners L.13, Tasset C.13, Van der Aa A.13, Harrison P.13

Created: Wednesday, 20 February 2019, 10:36 AM
OP024: Childhood-onset inflammatory bowel disease and risk of cancer – a Swedish nationwide cohort study 1964–2014
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Olén O.*1,2, Askling J.1, Frumento P.3, Sachs M.C.3, Neovius M.1, Eriksson J.1, Smedby K.E.1, Ekbom A.1, Malmborg P.1,2, Ludvigsson J.F.4,5,6,7

Created: Wednesday, 20 February 2019, 10:36 AM
OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014
Year: 2017
Source: ECCO'17 Barcelona
Authors: Olén O.
Last Modified: Wednesday, 15 March 2017, 2:27 PM by ECCO Administrator
IBD and malignancy, Lymphoma, Paediatric
Files: 1
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study
Year: 2018
Source: ECCO '18 Vienna
Authors:

G.R. D’Haens1*, W. Reinisch2, S.D. Lee3, D. Tarabar4, E. Louis5, M. Kłopocka6, J. Klaus7, S. Schreiber8, D.I. Park9, X. Hébuterne10, F. Cataldi11, A. Banerjee12, K. Gorelick13, W.J. Sandborn14

Created: Thursday, 21 February 2019, 9:14 AM
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study
Year: 2018
Source: ECCO'18 Vienna
Authors: D´Haens Geert R
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP024: Mucosal healing and dysplasia surveillance in a large referral Centre cohort of patients with Crohns disease and ulcerative colitis treated with vedolizumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Noman1, M. Ferrante1, R. Bisschops1, G. De Hertogh2, K. Van Den Broeck1, K. Rans1, P. Rutgeerts1, S. Vermeire1, G. Van Assche*1

Created: Friday, 22 February 2019, 9:49 AM
OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Bohm1, S.V. Sagi1, M. Fischer1, S. Kadire1, G. Tran1, M. Rahal1, S. Aniwan2, J. Meserve3, A. Weiss4, G. Kochhar5, P. Shashi5, D. Faleck6, A. Winters6, S. Chablaney6, J.L. Koliani-Pace7, B. Boland3, S. Singh3, R. Hirten6, E. Shmidt6, K. Lasch8, M. Luo8, D. Hudesman9, S. Chang9, D. Lukin4, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, S. Kane2, E.V. Loftus2, B.E. Sands6, W.J. Sandborn3, J.-F. Colombel6, B. Shen5, P.S. Dulai3*

Created: Thursday, 21 February 2019, 9:14 AM
OP025: Escalation of medical therapy decreases need for repeat dilatation in Crohns anastomatic strictures
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. S. Ding*1, 2, W. Yip1, R. Choi1, B. Saunders3, S. Thomas-Gibson3, N. Arebi1, A. Humphries3, A. Hart1

Created: Friday, 22 February 2019, 9:49 AM
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Steiner S.*1, King E.2, Park K.3, Pashankar D.4, Shashidhar H.5, Sudel B.6, Eichner S.7, Chen S.2, Pratt J.2, Colletti R.8 ImproveCareNow Network, Burlington, United States

Created: Wednesday, 20 February 2019, 10:36 AM
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn’s Disease in clinical practice
Year: 2017
Source: ECCO'17 Barcelona
Authors: Steiner S.
Last Modified: Wednesday, 15 March 2017, 2:24 PM by ECCO Administrator
Crohn's disease, Disease activity Indices, Adalimumab
Files: 1
OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Faleck1, P. Shashi2, J. Meserve3, M. Rahal4, S. Kadire4, G. Tran4, A. Weiss5, A. Winters1, S. Chablaney1, S. Aniwan6, J.L. Koliani-Pace7, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch8, M. Luo8, M. Bohm4, S. V Sagi4, M. Fischer4, D. Hudesman9, S. Chang9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, W.J. Sandborn3, B.E. Sands1, J.-F. Colombel1, S. Kane6, E.V. Loftus6, P.S. Dulai3*

Created: Thursday, 21 February 2019, 9:14 AM
OP026: The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohns disease following surgical resection in 240 patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

I. Arnott1, C. Mowat2, H. Ennis3, C. Keerie3, S. Lewis3, N. Kennedy4, A. Cahill5, A. Morris5, M. Dunlop6, S. Bloom7, J. Lindsay8, S. Subramanian9, J. Satsangi*4, TOPPIC Trial Study Group10

Created: Friday, 22 February 2019, 9:49 AM
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lahiff C.
Last Modified: Wednesday, 15 March 2017, 2:21 PM by ECCO Administrator
Colonoscopic surveillance, Chromoendoscopy, Colonoscopy, Dysplasia, UC colorectal cancer surveillance
Files: 1
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lahiff C.*1, Wang L.M.2, Travis S.P.L.1, East J.E.1

Created: Wednesday, 20 February 2019, 10:36 AM
OP027: Anti-tumour necrosis factor therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohns disease: outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Brouquet*1, L. Maggiori2, P. Zerbib3, J. Lefèvre4, Q. Denost5, A. Germain6, E. Cotte7, L. Beyer-Berjot8, N. Munoz-Bongrand9, V. Desfourneaux10, A. Rahili11, J.-P. Duffas12, K. Pautrat13, C. Denet14, V. Bridoux15, G. Meurette16, J.-L. Faucheron17, J. Loriau18, F. Guillon19, E. Vicaut20, S. Benoist1, Y. Panis2

Created: Friday, 22 February 2019, 9:49 AM
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer
Year: 2017
Source: ECCO'17 Barcelona
Authors: Lopetuso L.
Last Modified: Wednesday, 15 March 2017, 2:20 PM by ECCO Administrator
Epithelial cell, Fibroblast, Immunology
Files: 1
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in colitis-associated colorectal cancer
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lopetuso L.R.*1,2, De Salvo C.3, Di Martino L.3, Goodman W.3, Scaldaferri F.4, Gasbarrini A.4, Pizarro T.T.3

Created: Wednesday, 20 February 2019, 10:36 AM
OP027: SUCNR1 receptor mediates intestinal fibrosis
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Cosin-Roger1,2*, D. Ortiz-Masia2, D.C. Macias-Ceja1, L. Gisbert-Ferrandiz2, P. Salvador2, M. Hausmann3, G. Rogler3, S. Calatayud2, M.D. Barrachina2

Created: Thursday, 21 February 2019, 9:14 AM